Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur G. ESPOSITO |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Categorizing the cries of infants with ASD versus typically developing infants: A study of adult accuracy and reaction time / Marc H. BORNSTEIN in Research in Autism Spectrum Disorders, 31 (November 2016)
[article]
Titre : Categorizing the cries of infants with ASD versus typically developing infants: A study of adult accuracy and reaction time Type de document : Texte imprimé et/ou numérique Auteurs : Marc H. BORNSTEIN, Auteur ; K. COSTLOW, Auteur ; A. TRUZZI, Auteur ; G. ESPOSITO, Auteur Article en page(s) : p.66-72 Langues : Anglais (eng) Mots-clés : Cry Infancy Autism spectrum disorder Typical development Vocalizations Reaction time Index. décimale : PER Périodiques Résumé : AbstractBackground The cries of children with Autism Spectrum Disorder (ASD) contain atypical acoustic features. The cries of typically developing infants elicit automatic adult responses, but little is known about how the atypical cries of children with ASD affect the speed with which adults process them. Method. We used a reaction time (RT) categorical task to analyze adults’ categorization of typically developing cries, atypical (ASD) cries, mammalian animal cries, and environmental noise control sounds. 40 nonparent women (M age = 27 years) were instructed to categorize acoustic stimuli as human infant cries or non-human sounds as quickly as possible. Results. The RTs for correctly categorizing the cries of children with ASD (M = 831 ms, SEM = 27) were slower than RTs for typically developing child cries (M = 680 ms, SEM = 6) as well as mammalian animal cries (801 ms, SEM = 11) and environmental noise control sounds (M = 692 ms, SEM = 10). Conclusions. This difference may reflect difficulties in adults’ perceiving and processing atypical cries of children with ASD, and the findings may have implications for the parent-child relationship and for the quality of care children with ASD receive. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.08.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=295
in Research in Autism Spectrum Disorders > 31 (November 2016) . - p.66-72[article] Categorizing the cries of infants with ASD versus typically developing infants: A study of adult accuracy and reaction time [Texte imprimé et/ou numérique] / Marc H. BORNSTEIN, Auteur ; K. COSTLOW, Auteur ; A. TRUZZI, Auteur ; G. ESPOSITO, Auteur . - p.66-72.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 31 (November 2016) . - p.66-72
Mots-clés : Cry Infancy Autism spectrum disorder Typical development Vocalizations Reaction time Index. décimale : PER Périodiques Résumé : AbstractBackground The cries of children with Autism Spectrum Disorder (ASD) contain atypical acoustic features. The cries of typically developing infants elicit automatic adult responses, but little is known about how the atypical cries of children with ASD affect the speed with which adults process them. Method. We used a reaction time (RT) categorical task to analyze adults’ categorization of typically developing cries, atypical (ASD) cries, mammalian animal cries, and environmental noise control sounds. 40 nonparent women (M age = 27 years) were instructed to categorize acoustic stimuli as human infant cries or non-human sounds as quickly as possible. Results. The RTs for correctly categorizing the cries of children with ASD (M = 831 ms, SEM = 27) were slower than RTs for typically developing child cries (M = 680 ms, SEM = 6) as well as mammalian animal cries (801 ms, SEM = 11) and environmental noise control sounds (M = 692 ms, SEM = 10). Conclusions. This difference may reflect difficulties in adults’ perceiving and processing atypical cries of children with ASD, and the findings may have implications for the parent-child relationship and for the quality of care children with ASD receive. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.08.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=295 Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities / O. BRUNI in Journal of Child Psychology and Psychiatry, 59-5 (May 2018)
[article]
Titre : Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities Type de document : Texte imprimé et/ou numérique Auteurs : O. BRUNI, Auteur ; M. ANGRIMAN, Auteur ; F. CALISTI, Auteur ; A. COMANDINI, Auteur ; G. ESPOSITO, Auteur ; S. CORTESE, Auteur ; R. FERRI, Auteur Article en page(s) : p.489-508 Langues : Anglais (eng) Mots-clés : Sleep disorders drug effects insomnia neurodevelopmental disorders Index. décimale : PER Périodiques Résumé : BACKGROUND: Sleep disturbances, in particular insomnia, represent a common problem in children with neurodevelopmental disabilities (NDDs). Currently, there are no approved medications for insomnia in children by the US Food and Drug Administration or European Medicines Agency and therefore they are prescribed off-label. We critically reviewed pediatric literature on drugs as well as nonpharmacological (behavioral) interventions used for sleep disturbances in children with NDDs. METHODS: PubMed, Ovid (including PsycINFO, Ovid MEDLINE((R)) , and Embase), and Web of Knowledge databases were searched through February 12, 2017, with no language restrictions. Two authors independently and blindly performed the screening. RESULTS: Good sleep practices and behavioral interventions, supported by moderate-to-low level evidence, are the first recommended treatments for pediatric insomnia but they are often challenging to implement. Antihistamine agents, such as hydroxyzine or diphenhydramine, are the most widely prescribed sedatives in the pediatric practice but evidence supporting their use is still limited. An increasing body of evidence supports melatonin as the safest choice for children with NDDs. Benzodiazepines are not recommended in children and should only be used for transient insomnia, especially if daytime anxiety is present. Only few studies have been carried out in children's and adolescents' zolpidem, zaleplon, and eszopiclone, with contrasting results. Limited evidence supports the use of alpha-agonists such as clonidine to improve sleep onset latency, especially in attention deficit/hyperactivity disorder subjects. Tricyclic antidepressants, used in adults with insomnia, are not recommended in children because of their safety profile. Trazodone and mirtazapine hold promise but require further studies. CONCLUSIONS: Here, we provided a tentative guide for the use of drugs for insomnia in children with NDDs. Well-controlled studies employing both objective polysomnography and subjective sleep measures are needed to determine the efficacy, effectiveness, and safety of the currently prescribed pediatric sleep medicines in children with NDDs. En ligne : http://dx.doi.org/10.1111/jcpp.12812 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=359
in Journal of Child Psychology and Psychiatry > 59-5 (May 2018) . - p.489-508[article] Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities [Texte imprimé et/ou numérique] / O. BRUNI, Auteur ; M. ANGRIMAN, Auteur ; F. CALISTI, Auteur ; A. COMANDINI, Auteur ; G. ESPOSITO, Auteur ; S. CORTESE, Auteur ; R. FERRI, Auteur . - p.489-508.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 59-5 (May 2018) . - p.489-508
Mots-clés : Sleep disorders drug effects insomnia neurodevelopmental disorders Index. décimale : PER Périodiques Résumé : BACKGROUND: Sleep disturbances, in particular insomnia, represent a common problem in children with neurodevelopmental disabilities (NDDs). Currently, there are no approved medications for insomnia in children by the US Food and Drug Administration or European Medicines Agency and therefore they are prescribed off-label. We critically reviewed pediatric literature on drugs as well as nonpharmacological (behavioral) interventions used for sleep disturbances in children with NDDs. METHODS: PubMed, Ovid (including PsycINFO, Ovid MEDLINE((R)) , and Embase), and Web of Knowledge databases were searched through February 12, 2017, with no language restrictions. Two authors independently and blindly performed the screening. RESULTS: Good sleep practices and behavioral interventions, supported by moderate-to-low level evidence, are the first recommended treatments for pediatric insomnia but they are often challenging to implement. Antihistamine agents, such as hydroxyzine or diphenhydramine, are the most widely prescribed sedatives in the pediatric practice but evidence supporting their use is still limited. An increasing body of evidence supports melatonin as the safest choice for children with NDDs. Benzodiazepines are not recommended in children and should only be used for transient insomnia, especially if daytime anxiety is present. Only few studies have been carried out in children's and adolescents' zolpidem, zaleplon, and eszopiclone, with contrasting results. Limited evidence supports the use of alpha-agonists such as clonidine to improve sleep onset latency, especially in attention deficit/hyperactivity disorder subjects. Tricyclic antidepressants, used in adults with insomnia, are not recommended in children because of their safety profile. Trazodone and mirtazapine hold promise but require further studies. CONCLUSIONS: Here, we provided a tentative guide for the use of drugs for insomnia in children with NDDs. Well-controlled studies employing both objective polysomnography and subjective sleep measures are needed to determine the efficacy, effectiveness, and safety of the currently prescribed pediatric sleep medicines in children with NDDs. En ligne : http://dx.doi.org/10.1111/jcpp.12812 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=359